Medical News Today: Six yoga poses for prostate enlargement
Yoga has many benefits, In this article, learn about six yoga poses that can help ease and manage the symptoms of benign prostatic hyperplasia. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 18, 2017 Category: Consumer Health News Tags: Men's Health Source Type: news
Merit Medical licenses KatGuide pleural drain tech from Pleuratech
Merit Medical (NSDQ:MMSI) has licensed a novel surgical device designed to ensure drain placement in the pleural cavity from Pleuratech, according to a Young America Capital press release posted this week.
The device is Denmark-based Pleuratech’s flagship product, the KatGuide, and is designed to guide chest tubes to the part of the pleural cavity which needs draining to reduce misplaced drains and increase surgical success rates.
The companies did not release the exact terms of the deal, but said that it was a multimillion dollar license agreement, according to a press release.
“As a leading manufacturer and ...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Surgical Merit Medical Systems Inc. pleuratech Source Type: news
Photoselective Vaporization Bests Transurethral Resection of the Prostate for BPH Photoselective Vaporization Bests Transurethral Resection of the Prostate for BPH
Photoselective vaporization of the prostate (PVP) offers similar efficacy with better quality of life, compared with transurethral resection of the prostate (TURP), in men with benign prostatic hyperplasia (BPH), researchers from Italy report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 6, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news
How Teleflex Bagged a $1.1 Billion Hidden Treasure
Teleflex CEO Benson Smith expected some investors to be surprised by yet another billion-dollar acquisition, but sometimes businesses simply must strike while the iron is hot.
The Wayne, PA-based company said it will buy NeoTract for up to $1.1 billion. The deal comes just seven months after Teleflex completed its $1 billion acquisition of Vascular Solutions.
"I'm sure that at least some of you may be a bit surprised that Teleflex is once again active in M&A so quickly after announcing the acquisition of Vascular Solutions. Well, we are not," Smith said Tuesday during a conference call.
Smith said Teleflex has made sig...
Source: MDDI - September 5, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news
Teleflex to pay $1.1B for NeoTract
Teleflex (NYSE:TFX) said today that it agreed to put up $1.1 billion to acquire NeoTract and its UroLift prostate treatment.
The deal calls for an up-front cash payment of $725 million, plus another $375 million in milestone payments pegged to sales numbers through 2020, Wayne, Pa.-based Teleflex said. The deal is expected to close within 30 days.
The UroLift system for benign prostate hyperplasia uses tiny devices that are inserted into the urethra in a minimally invasive procedure to reopen the lower urinary tract by pushing aside tissue from the enlarged prostate. NeoTract put up sales of roughly $51 million last y...
Source: Mass Device - September 5, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Urology Wall Street Beat NeoTract Teleflex Source Type: news
NxThera adds $6m for Rez ūm prostate device
NxThera said this week that it added another $6 million to its coffers in an ongoing round of debt financing.
The Maple Grove, Minn.-based company is offering convertible promissory notes and Series C preferred stock warrants in the round, according to the filing, with the first sale logged Jan. 13.
NxThera said it’s looking to raise an additional $5.8 million in the round, taking the total hoped-for raise from $15 million to $26.4 million.
In Dec. 2015, Boston Scientific (NYSE:BSX) led a $40 million funding round for NxThera and its Rezūm device, saying it plans to boost its sales footprint in the U.S. and Europe...
Source: Mass Device - July 21, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Urology Wall Street Beat NxThera Inc. Source Type: news
7 medtech stories we missed this week: July 7, 2017
[Image from unsplash.com]From EnvisionTEC’s FDA approval to InVivo Therapeutics adding a new clinical site, here are seven medtech stories we missed this week but thought were still worth mentioning.
1. EnvisionTEC wins FDA nod for 3D printing E-Denture material
EnvisionTEC announced in a June 30 press release that it has received FDA approval for its E-Denture material for 3D printing dentures. The company already has the E-Dent 100 and 400 materials approved for the printing of restorations that simulate teeth. The new approval makes EnvisionTEC the only 3D printing company worldwide that has a complete digital den...
Source: Mass Device - July 7, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Clinical Trials Dental Food & Drug Administration (FDA) Imaging Implants Research & Development Adin Dental Implant Systems EnvisionTEC InVivo Therapeutics Life Spine Inc. MedTech NeoTract SpineGuard SpineWave Telerad Tech Ze Source Type: news
Tamsulosin and Naftopidil Offer Similar Benefits in BPH Tamsulosin and Naftopidil Offer Similar Benefits in BPH
Bladder storage symptoms associated with benign prostatic hyperplasia (BPH) improve to a similar extent with tamsulosin and naftopidil treatment, researchers from South Korea report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 30, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news
FDA grants de novo clearance for Merit Medical ’ s Embosphere
Merit Medical (NSDQ:MMSI) said yesterday that its Embosphere device won expanded de novo clearance from the to treat benign prostatic hyperplasia.
The federal safety watchdog’s clearance means Embosphere can be used in prostatic artery embolization procedures to treat BPH.
“Merit’s Embosphere is the first embolic agent to receive FDA 513(f)(2) classification for prostatic artery embolization, providing a non-surgical treatment option for millions of men who suffer from BPH,” chairman & CEO Fred Lampropoulos said in prepared remarks.
The device is designed to occlude the prostatic arteries...
Source: Mass Device - June 23, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Urology Merit Medical Systems Inc. Source Type: news
Popular prostate drug linked to serious side effects
(Boston University Medical Center) Treatment of benign prostatic hyperplasia (BPH) with the commonly prescribed Avodart (Dutsteride) may put men at an increased risk for diabetes, elevated cholesterol levels, non-alcoholic fatty liver disease (NAFLD) and worsening erectile dysfunction. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 22, 2017 Category: International Medicine & Public Health Source Type: news
2017 Eureka! Innovation award winner: NxThera Inc.
Industry category: Health Care Technology
Organization size: Small — revenue less than $50 million
Eureka! idea: Uses water vapor to treat endourological diseases that affect millions of men, with a safe, effective and fast procedure
What the judges said:"The team is great. It's a slick treatment option — killing cells in the gentle st way possible."
Benign prostatic hyperplasia, an enlargement of the prostate gland, affects 12 million men in the United States, with nearly 800,000 new diagnoses… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 21, 2017 Category: Biotechnology Source Type: news
2017 Eureka! Innovation award winner: NxThera Inc.
Industry category: Health Care Technology
Organization size: Small — revenue less than $50 million
Eureka! idea: Uses water vapor to treat endourological diseases that affect millions of men, with a safe, effective and fast procedure
What the judges said:"The team is great. It's a slick treatment option — killing cells in the gentle st way possible."
Benign prostatic hyperplasia, an enlargement of the prostate gland, affects 12 million men in the United States, with nearly 800,000 new diagnoses… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 21, 2017 Category: American Health Source Type: news
7 medtech stories we missed this week: May 26, 2017
[Image from unsplash.com]From Merck’s new licensing agreement to surgical study data being touted, here are 7 medtech stories we missed this week but thought were still worth mentioning.
1. Merck inks exclusive licensing agreement for Alzheimer’s antibody
Merck announced in a May 25 press release that it has entered an exclusive worldwide license agreement with Teijin Pharma. The licensing agreement is going to help with the development, manufacture and commercialization of an investigation preclinical antibody candidate that targets the protein tau. Merck will have exclusive worldwide rights to develop, manufa...
Source: Mass Device - May 26, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Patient Monitoring Pharma Pharmaceuticals Research & Development Surgical EarlySense Janssen Pharmaceuticals Life Spine Inc. Masimo MedTech Merck Midmark Procept BioRobotics Shenzhen Lachesis Mhealth Teijin Pharma Thermi Source Type: news
7 medtech stories we missed this week: May 19, 2017
[Image from unsplash.com]From FDA clearances to touting study data, here are 7 medtech stories we missed this week but thought were still worth mentioning.
1. XpandOrtho wins FDA 510(k) clearance
XpandOrtho announced in a May 17 press release that it has received FDA 510(k) clearance for its electronic soft tissue balancing instrument for total knee replacement surgery. The sterile-packaged wireless disposable device uses miniature sensors and actuators to balance knee joints during full-range motions. Using constant pressure bellows systems, the device communicates with a display for multiaxial balance and selection of th...
Source: Mass Device - May 19, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Clinical Trials Food & Drug Administration (FDA) Regulatory/Compliance Research & Development Body Vision Medical Exactech Inc. Lombard Medical Technologies MedTech NxThera Inc. Rivanna Medical Visionsense XpandOrtho Source Type: news
Enlarged Prostate (BPH, Benign Prostatic Hyperplasia)
Title: Enlarged Prostate (BPH, Benign Prostatic Hyperplasia)Category: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 5/18/2017 12:00:00 AM (Source: MedicineNet Mens Health General)
Source: MedicineNet Mens Health General - May 18, 2017 Category: Primary Care Source Type: news
